Your Friend Is on Mounjaro. Your Cousin Is on Wegovy. Which One Should Be Yours?
- Dr. Jan Dipasupil
- Apr 30
- 6 min read
The new problem in Philippine weight management is not scarcity. It is choice.
Four years ago, a woman who wanted medical help losing weight in Manila had a narrow menu and a physician willing to prescribe around it. Then Mounjaro arrived in January 2026, the first dual-action medication of its class, approved here for both obesity and type 2 diabetes, a breadth its American sibling Zepbound does not carry.
Wegovy followed in April, the dedicated weight-loss formulation of semaglutide, finally legal and locally stocked.
Two medications, both FDA PH approved, both available through physician-licensed clinics, both genuinely effective. The question is no longer whether to prescribe. The question is which one, and for whom.
The mainstream favourite
Wegovy is the one trending on her group chat. Semaglutide at 2.4mg, a weekly injection, the dedicated weight-loss formulation of the same molecule sold as Ozempic. Published data from the STEP trials puts the average weight loss at around fifteen percent at sixty-eight weeks. It arrived in Manila in April 2026 and has been the subject of more Instagram stories than any medication in recent memory. Its popularity is deserved. It is also, sometimes, not the right answer. Popularity is not a clinical indication.
The new standard
Mounjaro is the newer and the more potent. Tirzepatide, a weekly injection, and the first dual-action medication of its class, engaging both GLP-1 and GIP receptors in a single molecule. Published data from the SURMOUNT trials puts the average weight loss at roughly twenty percent at seventy-two weeks. It carries an unusual breadth of indication in the Philippines, approved for both obesity and type 2 diabetes, and it is already reshaping the conversation in medical weight management globally.
On paper, Mounjaro is the more effective of the two. In a consultation room, the word“effective” is only half the story.
The Woman Across The Desk
The woman across the desk rarely has a simple weight problem. She has a weight problem that sits inside a sleep problem. She has appetite patterns that shift with her cycle, or with a grief she has not fully named, or with the pressure of a career that eats her lunch hour four days out of five. She has food feelings. She has mood weather. She has a thyroid that may or may not be cooperating, and a relationship with the scale that is older than her oldest friendship.
A GLP-1 medication will address a portion of this. It will not address all of it. Any physician who pretends otherwise is selling, not prescribing.
“Weight is the easiest thing to measure and the hardest thing to explain,” Dr. Jan says. “The scale is the last indicator to change. What comes first is sleep, mood, energy, appetite, the relationship with food. We assess those. The medication is one instrument in a larger protocol.”
The Assessment
Both Jan Medical Group branches, Bonifacio Global City and Quezon City, run full-body composition analysis at the first consultation and at every checkpoint thereafter. Not a scale. An analyzer that resolves the numbers that actually matter: lean muscle mass, visceral fat, body water, basal metabolic rate, skeletal muscle index, and fat distribution by body segment.
This matters for a specific reason. A woman can lose twenty pounds on Wegovy or Mounjaro and lose a disproportionate amount of muscle with it, a well-documented side effect of rapid GLP-1 weight loss that the bathroom scale will not reveal. The analyzer will. And the analyzer is what tells us, session after session, whether the weight being lost is the right kind of weight.
This is the foundation on which the prescription is built. Not her friend’s experience on Mounjaro. Not the brand name she heard on a podcast. Her own physiology, measured properly, at the start and at every checkpoint along the way.
The Philosophy
Five years ago, the conversation in a medical weight loss consultation in Manila was about what to do in the absence of good options. Today, the conversation is about which of several good options fits this specific client.
“Before, we had maybe two medications, and the conversation was about compromise,”Dr. Jan says. “Today we have Wegovy and Mounjaro, and soon we will have more. It is a different moment in medicine. But abundance is not an excuse for laziness. We do not prescribe the most popular medication. We prescribe the one tailored to the client.”
The Programme
At Jan Medical Group, medical weight management is never the medication alone. It is the prescription paired with a lifestyle protocol: nutrition calibrated to the client’s actual metabolic rate as measured, not estimated; sleep hygiene; resistance training to protect against the muscle loss that haunts GLP-1 therapy; and quarterly body composition reassessment to confirm that the silhouette change is the right kind of silhouette change.
Two medications. One client. One tailored programme. That is the work.
Medical weight management consultations are available at both Jan Medical Group branches, Bonifacio Global City and Quezon City. Consultations with Jan Paolo P. Dipasupil, MD, and the physicians of Jan Medical Group are by appointment. Enquiries: clinic@janmedicalgroup.ph.
Quick Reference
Mounjaro and Wegovy, briefly
Wegovy (semaglutide 2.4mg) is a weekly GLP-1 injection, the dedicated weight-loss formulation of the same molecule sold as Ozempic. Launched in the Philippines in April 2026. Average weight loss in published trials is around fifteen percent at sixty-eight weeks. The most widely discussed GLP-1 medication in the Philippine market by volume of social media conversation.
Mounjaro (tirzepatide) is a weekly dual-action injection that engages both GLP-1 and GIP receptors in a single molecule. Launched in the Philippines in January 2026 with a dual indication for both obesity and type 2 diabetes, a breadth its American sibling Zepbound does not carry. Average weight loss in published trials is around twenty percent at seventy-two weeks, the highest among currently approved weight-loss medications in the Philippines.
Both are FDA PH approved and available through physician-licensed clinics.
Frequently asked questions
Q: What is the difference between Mounjaro and Wegovy? Both are weekly injectable GLP-1 weight-loss medications, but they differ in molecule, mechanism, and potency. Wegovy (semaglutide) acts on the GLP-1 receptor only. Mounjaro (tirzepatide) acts on both the GLP-1 and GIP receptors in a single molecule, which is why it is described as dual-action. In published trials, Mounjaro produces higher average weight loss than Wegovy, though the most effective medication on paper is not always the most appropriate for every client.
Q: Which is more effective, Mounjaro or Wegovy? Mounjaro produces higher average weight loss in published trials, at roughly twenty percent at seventy-two weeks (SURMOUNT data), compared to roughly fifteen percent at sixty-eight weeks for Wegovy (STEP data). However, most effective on paper is not the same as most appropriate for every client. Clinical factors, medical history, comorbidities, budget, and lifestyle all influence the right prescription.
Q: Are Mounjaro and Wegovy available in the Philippines? Yes. Both are FDA PH approved. Mounjaro launched in the Philippines in January 2026 with a dual indication for obesity and type 2 diabetes. Wegovy launched in April 2026.
Q: How does Jan Medical Group decide which medication to prescribe? The decision is based on a full clinical consultation and full-body composition analysis, run at both JMG branches. Factors include the client’s body composition (lean mass, visceral fat, metabolic rate), medical history, lifestyle and schedule constraints, comorbidities such as type 2 diabetes, and personal goals. The most popular medication is not automatically the one prescribed.
Q: What is a body composition analyzer? A body composition analyzer is a medical-grade device that measures lean muscle mass, visceral fat, body water, basal metabolic rate, skeletal muscle index, and fat distribution by body segment. It is more accurate and more useful than a bathroom scale for medical weight management. Both Jan Medical Group branches run full-body composition analysis at every checkpoint of the programme.
Q: Can I switch from Wegovy to Mounjaro, or the other way around? Yes, under medical supervision. Reasons for switching include plateau, side effects, supply availability, cost considerations, or a change in clinical goals. Switching between GLP-1 medications requires a physician-supervised washout and re-titration, not a simple substitution.
Q: Why is a lifestyle protocol important if I am already on Mounjaro or Wegovy? GLP-1 medications work by reducing appetite and slowing gastric emptying, which produces weight loss. They do not protect lean muscle mass, they do not improve sleep quality directly, and they do not resolve the emotional and behavioural patterns around food. Without a lifestyle protocol (nutrition, sleep, resistance training, stress management), rapid GLP-1 weight loss frequently includes significant muscle loss and an incomplete resolution of the underlying drivers. The lifestyle protocol is not an add-on. It is the treatment.
Q: Where can I get a medical weight loss consultation in the Philippines? Jan Medical Group offers physician-led medical weight management at both its Bonifacio Global City and Quezon City branches. Consultations include full-body composition analysis and a personalised treatment plan.
About the author
Jan Paolo P. Dipasupil, MD is the medical director of Jan Medical Group, a physician-led medical aesthetics and wellness clinic with flagships in Bonifacio Global City, Taguig and Quezon City. He is Vice President at the Philippine Digital Medicine Society (PDMS). His clinical practice integrates obesity medicine and lifestyle medicine, with a particular focus on the post-weight-loss client on GLP-1 therapy.
Comments